Latin America Human Immunodeficiency Virus Therapeutics Market Size & Outlook
Related Markets
Latin America human immunodeficiency virus therapeutics market highlights
- The Latin America human immunodeficiency virus therapeutics market generated a revenue of USD 450.1 million in 2023.
- The market is expected to grow at a CAGR of 3.4% from 2024 to 2030.
- In terms of segment, branded drugs was the largest revenue generating drug type in 2023.
- Branded Drugs is the most lucrative drug type segment registering the fastest growth during the forecast period.
Latin America data book summary
| Market revenue in 2023 | USD 450.1 million |
| Market revenue in 2030 | USD 567.3 million |
| Growth rate | 3.4% (CAGR from 2023 to 2030) |
| Largest segment | Branded drugs |
| Fastest growing segment | Branded Drugs |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Branded Drugs |
| Key market players worldwide | AbbVie Inc, Boehringer Ingelheim, Bristol-Myers Squibb Co, Cipla Ltd DR, Genentech, Gilead Sciences Inc, Merck & Co Inc, ViiV Healthcare |
Other key industry trends
- In terms of revenue, Latin America region accounted for 4.4% of the global human immunodeficiency virus therapeutics market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,055.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Human Immunodeficiency Virus Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| ViiV Healthcare | View profile | 501-1000 | London, England, United Kingdom, Europe | http://www.viivhealthcare.com |
| Genentech | View profile | 10001+ | South San Francisco, California, United States, North America | http://gene.com |
| Gilead Sciences Inc | View profile | 18000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | https://www.gilead.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | https://www.boehringer-ingelheim.com/ |
| Cipla Ltd DR | View profile | 38955 | Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, India, 400 013 | https://www.cipla.com |
| Bristol-Myers Squibb Co | View profile | 34100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | https://www.bms.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
Latin America human immunodeficiency virus therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to human immunodeficiency virus therapeutics market will help companies and investors design strategic landscapes.
Branded drugs was the largest segment with a revenue share of 100% in 2024. Horizon Databook has segmented the Latin America human immunodeficiency virus therapeutics market based on branded drugs covering the revenue growth of each sub-segment from 2018 to 2030.
Reasons to subscribe to Latin America human immunodeficiency virus therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Latin America human immunodeficiency virus therapeutics market databook
-
Our clientele includes a mix of human immunodeficiency virus therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America human immunodeficiency virus therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America human immunodeficiency virus therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
